Regeneron Pharmaceuticals Income Statement
REGN / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
Regeneron Pharmaceuticals reported $14.3B in revenue and $4.5B in net income for FY2025. Revenue has grown at a 29.6% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.3B | $14.2B | $13.1B | $8.5B | $6.6B | $5.1B | $6.6B | $5.1B | $1.3B | $4.9B | $4.1B | $2.8B | $445.8M | $1.4B | $379.3M |
| Cost of Revenue | - | - | - | - | - | $237.5M | $402.8M | $237.5M | $202.5M | $194.6M | $241.7M | $129.0M | $4.2M | $83.9M | $1.7M |
| SG&A Expense | $2.7B | $3.0B | $2.6B | $1.3B | $1.3B | $1.1B | $1.3B | $1.1B | $1.3B | $1.2B | $838.5M | $519.3M | $117.3M | $210.8M | $52.9M |
| R&D Expense | $5.9B | $5.1B | $4.4B | $2.6B | $2.5B | $1.5B | $2.5B | $1.5B | $2.1B | $2.1B | $1.6B | $1.3B | $529.5M | $625.6M | $398.8M |
| Operating Income | $3.6B | $4.0B | $4.0B | $3.6B | $2.2B | $2.5B | $2.2B | $2.5B | $2.1B | $1.3B | $1.3B | $823.9M | -$205.2M | $457.7M | -$74.1M |
| Interest Expense | - | - | $73.0M | $56.9M | $30.2M | $28.2M | $30.2M | $28.2M | $25.1M | $7.2M | $14.2M | $37.4M | $21.3M | $45.3M | $2.3M |
| Income Tax | $725.8M | $367.3M | $245.7M | $297.2M | $313.3M | $109.1M | $313.3M | $109.1M | $880.0M | $434.3M | $589.0M | $423.1M | -$1.1M | -$335.8M | -$4.1M |
| Net Income | $4.5B | $4.4B | $4.0B | $3.5B | $2.1B | $2.4B | $2.1B | $2.4B | $1.2B | $895.5M | $636.1M | $338.1M | -$221.8M | $750.3M | -$67.8M |
| EPS (Basic) | $37.05 | $40.51 | $76.40 | $32.65 | $19.38 | $22.65 | $11.27 | $8.55 | $6.17 | $3.36 | $4.23 | $7.92 | -$2.45 | -$1.26 | - |
| EPS (Diluted) | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 | $5.52 | $2.98 | $3.72 | $6.75 | -$2.45 | -$1.26 | -$0.85 |
| Shares Outstanding | 113.7M | 113.5M | 112.2M | 115.1M | 114.6M | 114.8M | 115.9M | 116.3M | 115.2M | 113.4M | 111.3M | 115.4M | 90.6M | 82.9M | 87.2M |
| Operating Margin | 24.9% | 28.1% | 30.9% | 42.1% | 33.7% | 49.3% | 33.7% | 49.3% | 157.7% | 27.4% | 30.5% | 29.2% | -46.0% | 33.2% | -19.5% |
| Profit Margin | 31.4% | 31.1% | 30.1% | 41.3% | 32.3% | 47.5% | 32.3% | 47.5% | 90.9% | 18.4% | 15.5% | 12.0% | -49.7% | 54.4% | -17.9% |